DarioHealth Corp. (DRIO) Financial Statements (2026 and earlier)

Company Profile

Business Address 322 W 57TH ST. #33B
NEW YORK, NY 10019
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3841 - Surgical and Medical Instruments and Apparatus (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments21,80331,90721,95427,85427,76415,547
Cash and cash equivalent21,80331,90721,95427,85427,76415,547
Short-term investments      
Restricted cash and investments229222218192175663
Receivables(158)(175)(156)(191)(169)(200)
Inventory, net of allowances, customer advances and progress billings4,3164,8694,6094,6224,7534,742
Inventory4,3164,8694,6094,6224,7534,742
Prepaid expense 1,576   1,788 
Deferred costs258274285282259235
Other current assets 527   289 
Other undisclosed current assets6,5165,0885,2605,8035,6708,541
Total current assets:35,06742,18532,17038,56240,52929,528
Noncurrent Assets
Operating lease, right-of-use asset7177468619551,0651,306
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization5495786106467091,235
Intangible asset, including goodwill, after accumulated amortization73,35873,83274,30575,02776,18977,770
Goodwill57,42757,42757,42757,42757,42757,427
Intangible asset, excluding goodwill, after accumulated amortization15,93116,40516,87817,60018,76220,343
Deposits noncurrent assets80797979796
Deferred costs176160136866553
Other undisclosed noncurrent assets12814716424524855
Total noncurrent assets:75,00875,54276,15577,03878,35580,425
TOTAL ASSETS:110,075117,727108,325115,600118,884109,953
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5,3303,4693,3792,7454,9852,655
Accounts payable2,9283,4693,3792,7453,0452,655
Accrued liabilities 2,402   1,940 
Deferred revenue7148607271,3051,5831,118
Debt    10,2955,4518,670
Other undisclosed current liabilities3,2794,9505,6484,8104,6166,403
Total current liabilities:9,3239,2799,75419,15516,63518,846
Noncurrent Liabilities
Long-term debt and lease obligation30,74730,61730,49918,89923,47220,187
Long-term debt, excluding current maturities30,74730,61730,49918,89923,47220,187
Liabilities, other than long-term debt2,0832,8974,0863,8476,75812,409
Other liabilities467481912549
Operating lease, liability5715796126537651,033
Derivative instruments and hedges, liabilities1,4662,2443,3933,1035,96811,327
Total noncurrent liabilities:32,83033,51434,58522,74630,23032,596
Total liabilities:42,15342,79344,33941,90146,86551,442
Equity
Equity, attributable to parent67,92274,93463,98673,69972,01958,511
Common stock444443
Additional paid in capital519,996516,756486,953478,104462,358436,590
Accumulated deficit(452,078)(441,826)(422,971)(404,409)(390,343)(378,082)
Total equity:67,92274,93463,98673,69972,01958,511
TOTAL LIABILITIES AND EQUITY:110,075117,727108,325115,600118,884109,953

Income Statement (P&L) ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues5,2315,0075,3696,7527,6047,423
Cost of revenue
(Cost of Product and Service Sold)
(2,427)(1,992)(2,405)(2,870)(3,402)(3,546)
Gross profit:2,8043,0152,9643,8824,2023,877
Operating expenses(11,366)(12,499)(12,164)(13,291)(15,870)(15,907)
Operating loss:(8,562)(9,484)(9,200)(9,409)(11,668)(12,030)
Nonoperating income (expense)(386)(982)(3,790)2042,191(313)
Investment income, nonoperating (701)175237289161 
Gain (loss), foreign currency transaction, before tax 211(49)(204)42(58) 
Other nonoperating income711175    
Interest and debt expense(1,097)(1,157)    
Loss from continuing operations before equity method investments, income taxes:(10,045)(11,623)(12,990)(9,205)(9,477)(12,343)
Other undisclosed income from continuing operations before income taxes1,0971,157    
Loss from continuing operations before income taxes:(8,948)(10,466)(12,990)(9,205)(9,477)(12,343)
Income tax expense (benefit)(83)  (22)(155)13
Net loss available to common stockholders, diluted:(9,031)(10,466)(12,990)(9,227)(9,632)(12,330)

Comprehensive Income ($ in thousands)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(9,031)(10,466)(12,990)(9,227)(9,632)(12,330)
Comprehensive loss:(9,031)(10,466)(12,990)(9,227)(9,632)(12,330)
Other undisclosed comprehensive loss, net of tax, attributable to parent (1,221)(8,389)(5,572)(4,839)(2,629)(2,278)
Comprehensive loss, net of tax, attributable to parent:(10,252)(18,855)(18,562)(14,066)(12,261)(14,608)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: